Latest
Sierra x Acquired NYC: Bret Taylor on the AI ParadoxSierra x Acquired NYC: Bret Taylor on the AI Paradox|Clair Health Raises $11.6M Seed to Bring Continuous Hormone Monitoring Into the Wearable EraClair Health Raises $11.6M Seed to Bring Continuous Hormone Monitoring Into the Wearable Era|Orthogonal Raises $4.3M Seed to Build the Infrastructure Layer for AI AgentsOrthogonal Raises $4.3M Seed to Build the Infrastructure Layer for AI Agents|Tugboat Raises $3M Seed Round as Insurance Claims Become a Climate-Era ProblemTugboat Raises $3M Seed Round as Insurance Claims Become a Climate-Era Problem|fomo Raises $75M Series B as Social Trading Moves Mainstreamfomo Raises $75M Series B as Social Trading Moves Mainstream|DropGenie’s Seed+ Round Signals a New Era for Primary-Cell Drug DiscoveryDropGenie’s Seed+ Round Signals a New Era for Primary-Cell Drug Discovery|HistoSonics Raises $250M in Growth Financing as Histotripsy Moves Into the MainstreamHistoSonics Raises $250M in Growth Financing as Histotripsy Moves Into the Mainstream|Upscale AI Raises $190M Series A at a $2B Valuation as the Battle for AI Networking Heats UpUpscale AI Raises $190M Series A at a $2B Valuation as the Battle for AI Networking Heats Up|Nura Bio Raises $73.8M Series B to Advance SARM1 NeuroprotectionNura Bio Raises $73.8M Series B to Advance SARM1 Neuroprotection|Vedana Therapeutics Raises $46M Series A to Advance Next-Generation Migraine TherapiesVedana Therapeutics Raises $46M Series A to Advance Next-Generation Migraine Therapies|Sierra x Acquired NYC: Bret Taylor on the AI ParadoxSierra x Acquired NYC: Bret Taylor on the AI Paradox|Clair Health Raises $11.6M Seed to Bring Continuous Hormone Monitoring Into the Wearable EraClair Health Raises $11.6M Seed to Bring Continuous Hormone Monitoring Into the Wearable Era|Orthogonal Raises $4.3M Seed to Build the Infrastructure Layer for AI AgentsOrthogonal Raises $4.3M Seed to Build the Infrastructure Layer for AI Agents|Tugboat Raises $3M Seed Round as Insurance Claims Become a Climate-Era ProblemTugboat Raises $3M Seed Round as Insurance Claims Become a Climate-Era Problem|fomo Raises $75M Series B as Social Trading Moves Mainstreamfomo Raises $75M Series B as Social Trading Moves Mainstream|DropGenie’s Seed+ Round Signals a New Era for Primary-Cell Drug DiscoveryDropGenie’s Seed+ Round Signals a New Era for Primary-Cell Drug Discovery|HistoSonics Raises $250M in Growth Financing as Histotripsy Moves Into the MainstreamHistoSonics Raises $250M in Growth Financing as Histotripsy Moves Into the Mainstream|Upscale AI Raises $190M Series A at a $2B Valuation as the Battle for AI Networking Heats UpUpscale AI Raises $190M Series A at a $2B Valuation as the Battle for AI Networking Heats Up|Nura Bio Raises $73.8M Series B to Advance SARM1 NeuroprotectionNura Bio Raises $73.8M Series B to Advance SARM1 Neuroprotection|Vedana Therapeutics Raises $46M Series A to Advance Next-Generation Migraine TherapiesVedana Therapeutics Raises $46M Series A to Advance Next-Generation Migraine Therapies
Back to articles
•

The Carlyle Group Invests $400M+ to Build AI-Native Healthcare RCM Platform via Knack RCM and EqualizeRCM Combination

Money moves quiet… until it doesn’t. Then it echoes like The Carlyle Group stepping into healthcare revenue cycle management with intent, not noise. Carlyle brought Knack RCM and EqualizeRCM under one roof, shaping an AI-native platform with $400M behind it and a structure that reaches $600M including debt. This isn’t capital chasing headlines. This is capital building infrastructure.

The foundation starts with operators who’ve lived inside the problem. Rajiv Sharma built Knack Global in 2007 from Woodbridge, New Jersey, turning inefficiency into a target. Nagi Rao launched EqualizeRCM in 2004 out of Austin, Texas, leaning into the complexity of physician groups, rural hospitals, and specialty care. Both founders stayed in and reinvested. That’s not sentiment. That’s signal.

Carlyle didn’t improvise the math. Knack RCM carried a $500M valuation from August 2024. EqualizeRCM came in at $200M. The assembly is deliberate, backed by Carlyle Asia Partners VI and Carlyle Asia Partners Growth II, aimed straight at a fragmented market that’s been waiting for someone to connect the dots without breaking the system.

Now the room where decisions get made feels crowded in the best way. Gautam Barai steps in as CEO, with Rajiv Sharma continuing as Founder and President, and Nagi Rao as Founder and Executive Chairman. On the investment side, Neeraj Bharadwaj, Kapil Modi, and Amit Jain are driving the thesis into execution. Above that layer sits Carlyle’s broader leadership engine, where Harvey M. Schwartz operates as CEO, alongside founders William E. Conway, Jr., David M. Rubenstein, and Daniel A. D’Aniello, with a bench that includes Justin Plouffe as CFO, Lindsay LoBue as COO, John Redett and Mark Jenkins as Co-Presidents, Jeff Nedelman leading client strategy, and Lúcia Soares steering technology transformation. Different seats, same table, all aligned on scale.

The product is where it sharpens. An AI-native, multi-specialty RCM platform built to reduce friction across billing, coding, credentialing, and collections. Not theory. Execution across the United States, India, and the Philippines, designed to accelerate payments and tighten outcomes where delays used to hide.

Healthcare is shifting toward value-based care while margins get thinner and talent gets tighter. Complexity isn’t leaving, it’s compounding. So the ones who can turn chaos into clarity don’t just win deals, they become essential. Carlyle sees the flow of money as the real battleground, and right now, they’re placing pieces where the system can’t ignore them.

The Carlyle Group

The Carlyle Group

Global alternative asset management and private equity firm investing across multiple sectors

Website

Key Executives

  • Harvey M. Schwartz (CEO)
  • William E. Conway
+9 more (coming soon)

Related Articles

More from Jesse Landry

Trending

View all posts